- Title
- (372) - A Phase 2b Randomized Controlled Trial of Presatovir, an Oral RSV Fusion Inhibitor, for the Treatment of Respiratory Syncytial Virus (RSV) in Lung Transplant (LT) Recipients
- Creators
- J. Gottlieb - Hannover Medical School, Hannover, GermanyF. Torres - The University of Texas Southwestern Medical CenterT. Haddad - Tampa General HospitalG. Dhillon - Stanford MedicineD.F. Dilling - Loyola University ChicagoC. Knoop - Universitair Ziekenhuis BrusselR. Rampolla - Ochsner Clinic Foundation, New Orleans, LAR. Walia - St. Joseph's Hospital and Medical CenterV. Ahya - University of PennsylvaniaR. Kessler - University of Strasbourg, Strasbourg, FranceD.P. Mason - Baylor University Medical CenterM. Budev - Cleveland ClinicC. Neurohr - Ludwig-Maximilians-Universität MünchenA.R. Glanville - St Vincent's Hospital MelbourneR. Jordan - Gilead Sciences Inc., Foster City, CAD. Porter - Gilead Sciences Inc., Foster City, CAM.T. McKevitt - Gilead SciencesP. German - Gilead Sciences Inc., Foster City, CAY. Guo - Gilead Sciences Inc., Foster City, CAJ.W. Chien - Gilead Sciences Inc., Foster City, CAT.R. Watkins - Gilead Sciences Inc., Foster City, CAM. Zamora - Denver Health Medical Center
- Publication Details
- The Journal of heart and lung transplantation, Vol.37(4), pp.S155-S155
- Publisher
- Elsevier Inc
- Identifiers
- 991006228459002656
- Academic Unit
- Internal Medicine
- Language
- English
- Resource Type
- Journal article
Journal article
(372) - A Phase 2b Randomized Controlled Trial of Presatovir, an Oral RSV Fusion Inhibitor, for the Treatment of Respiratory Syncytial Virus (RSV) in Lung Transplant (LT) Recipients
The Journal of heart and lung transplantation, Vol.37(4), pp.S155-S155
04/2018
Metrics
1 Record Views